What is Altreno?
Altreno is a biosimilar version of trastuzumab (the active ingredient in Herceptin). It was approved by the U.S. Food and Drug Administration in 2023 for treating HER2‑positive breast and gastric cancers in adults and children, as well as HER2‑positive metastatic breast cancer in patients who have received prior treatment for metastatic disease [1][2].
How does Altreno work compared to the original drug?
Altreno targets the HER2 receptor on cancer cells, blocking cell growth signals and triggering immune‑mediated killing of tumor cells. The FDA’s biosimilarity assessment confirmed that Altreno’s structure, pharmacokinetics, and clinical efficacy are highly similar to those of reference trastuzumab, with no clinically meaningful differences in safety or effectiveness [1].
What cancers is Altreno approved for?
The label includes:
- HER2‑positive metastatic or unresectable locally advanced breast cancer in patients who have received prior HER2‑targeted therapy
- HER2‑positive metastatic gastric or gastro‑esophageal junction cancer in adults and children
- HER2‑positive metastatic breast cancer in patients who have progressed after at least one line of HER2‑targeted therapy (including trastuzumab) in the metastatic setting [1].
What are the common side effects?
Like reference trastuzumab, Altreno’s side‑effect profile includes infusion reactions, nausea, vomiting, diarrhea, and cardiotoxicity (reduced left‑ventricular ejection fraction). The clinical trials did not reveal new safety signals. Patients with pre‑existing heart conditions should undergo baseline cardiac evaluation [1].
How do I qualify for Altreno treatment?
Eligibility mirrors that of trastuzumab: a confirmed HER2‑positive tumor, measurable disease, and prior HER2 therapy (if indicated). Physicians must confirm the patient’s diagnosis and HER2 status per standard diagnostic protocols before prescribing Altreno. Insurance coverage usually follows the same criteria as for trastuzumab, but coverage may vary by plan [2].
What is the pricing and reimbursement landscape?
Altreno’s manufacturer, Pfizer, has positioned it at a lower price point than reference trastuzumab to encourage uptake. Medicare and private insurers typically offer similar reimbursement rates to other trastuzumab biosimilars, but the specific dollar amount depends on negotiated contracts and pharmacy benefit manager arrangements. Patients may also qualify for manufacturer patient assistance programs for uninsured or underinsured individuals [2].
Who are the main competitors in the HER2‑targeted biosimilar market?
Other trastuzumab biosimilars approved in the U.S. include Ogivri (Merck KGaA), Herzuma (Hoffmann‑La Roche), and Rukobia (Horizon Therapeutics). Each product follows a comparable biosimilar approval pathway and targets the same indications, creating a competitive landscape that is driving price reductions and expanding access [2].
What is the patent situation for Altreno?
Altreno is a biosimilar; its approval does not involve a new patent on the active ingredient. However, the original trastuzumab patents (including formulation, labeling, and certain manufacturing processes) have expired or are set to expire in the next decade, which allows multiple biosimilars to enter the market. Pfizer’s marketing agreement for Altreno does not extend exclusivity beyond the standard biosimilar pathway [1].
How was Altreno approved by the FDA?
The approval process followed the 2015 FDA guidance for biosimilar drugs, requiring extensive analytical characterization, non‑clinical testing, and a pivotal clinical study demonstrating similarity to reference trastuzumab in terms of efficacy and safety. The pivotal trial enrolled over 1,200 patients across several cancer types and met all primary endpoints [1].
Will new biosimilars enter the market before patent expiry?
Yes, biosimilars can file for approval once the reference product’s patents expire or when the manufacturer’s exclusivity period ends. In the trastuzumab space, several biosimilars were approved before the original patents expired, indicating that future entrants are likely as the market matures. Pfizer’s Altreno is part of this wave, aiming to provide a cost‑effective alternative while maintaining therapeutic equivalence [1][2].
Are there any controversies or regulatory challenges?
The main regulatory discussion involves the interpretation of “no clinically meaningful differences” and how equivalence in efficacy is assessed across diverse tumor types. Additionally, payers and patients sometimes question whether biosimilars can truly match the reference drug’s safety profile, especially concerning rare cardiotoxic events. FDA continues to monitor post‑marketing data to confirm long‑term safety and effectiveness [1].
Sources
[1] FDA. “FDA approves Pfizer’s Altreno biosimilar for HER2‑positive breast and gastric cancers.” https://www.fda.gov/news-events/press-announcements/fda-approves-pfizer-s-altreno-biosimilar-her2-positive-breast-gastric-cancers.
[2] Pfizer. “Altreno (trastuzumab) – FDA approval.” https://www.pfizer.com/products/altreno.